<DOC>
	<DOCNO>NCT01041690</DOCNO>
	<brief_summary>Reports use intravitreal bevacizumab ( Avastin , Genentech ) reduction neovascularization proliferative diabetic retinopathy demonstrate significant regression number new vessel . Reducing vascularity neovascular fibrovascular tissue potentially reduce bleed intraoperatively thus facilitate vitrectomy procedure . The investigator choose investigate potential benefit use preoperative bevacizumab management complex case .</brief_summary>
	<brief_title>Efficacy PreOperative Bevacizumab Diabetic Eye Disease</brief_title>
	<detailed_description>PURPOSE : To evaluate role preoperative intravitreal bevacizumab adjunct vitrectomy management severe diabetic eye disease . SETTINGS : Kasr El-Aini Teaching Hospital - Cairo University 2007 2008 . METHODS : Twenty eye 19 patient severe proliferative diabetic retinopathy recruit study . All eye underwent single intravitreal injection bevacizumab 1.25 mg 0.05 ml one week prior vitrectomy tractional ( 14 ) , combine tractional/rhegmatogenous retinal detachment ( 4 ) , fibrovascular tissue covering/distorting macula ( 2 ) . Exclusion criterion : previous vitrectomy , neovascular glaucoma , dense medium opacity ( dense cataract vitreous hemorrhage ) preclude fluorescein angiography ( FA ) do pre- 1 week post injection . Best correct visual acuity ( BCVA ) , anterior segment dilate fundus examination , intraocular pressure ( IOP ) , do pre- , 1 week post-injections , 1 day , 1 week monthly 3 month post-vitrectomy . Intra- post-operative bleeding record .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Tractional Retinal Detachment involve threaten macula , Tractional+Rhegmatogenous Retinal Detachment , Fibrovascular tissue cover distort macula . Vitrectomy Neovascular glaucoma Dense medium opacity ( dense cataract vitreous hemorrhage ) preclude fluorescein angiography ( FA )</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
	<keyword>Vitrectomy</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>